Time to buy hasn't arrived yet. People bought at
70s, 60s, or 50s. I understand you. But don't rush to
buy because BSX's cycle bottom is lower 40s. I think
I will buy at around maybe $45 or so. Be patient,
with the current bad news, earnings shortfall, the
worst is NOT over.
Not BSX, they will need to take large reserves
against shipments. Not only for NIR on SOX but for more.
Expect that some will return NIR w/ or w/o. If you were
the doctor would you take a chance? Any problem w/any
NIR could lead to malpractice suits. I would return
everything on my shelf!!!
Did someone die under the Nir procedure? Is that
why BSX is getting out of the stent business? Check
BSX Message #l267??
AVEI should rally tomorrow and
the shorts will have to cover making the stock go to
$48 or so... before great earnings on the l5th... and
the medical conference on Oct. 7th.
Go gte an MRI. You must have hit you're head very
hard. The Nir no ranger is exciting to no one. 50%
market share is a BSX dream that will never be realized.
The waqllstent and the radius are curiosities that
the sales force themselves will never push.
I couldn't agree with your assessment any more.
No patient issues?? AMAZING!!!! They wouldn't say
that if their father was rushed to emergency surgery
because the thing failed to operate as advertised.
35% marketshare for the Nir-on Ranger??
Exceedingly well in Europe?? You need to stop listening to
your Scimed regional manager, and get a real job. THis
is an investment forum with exchanges on where the
company is heading, not a sales rep's forum to try to
convince the investment community that everything is A-OK
with this product line, when everyone knows it isn't.
I would say going to emergency open heart surgery
after a balloon rupture at low pressure in which the
stent does not get fully deployed along with arterial
dissection is harming the patient just a bit. You get your
facts straight...there are several well known hospitals
that have pulled the Sox product from their shelves
after multiple incidents. Here are some facts: Scimed
reps strongly promoted aggressive primary stenting
right out of the chute, then when the problems
surfaced, their CFO blamed it on operator error. Then they
covered their butts by sending out a doctor letter saying
they do not encourage primary stenting and always
recommend pre-dilatation. Now they have ceased
manufacturing the product but have not pulled it off shelves
and the problem is still occurring. I call that very
irresponsible bordering on unethical. I wonder if the FDA would
I've heard they won't make it. They may have to
take reserves for NIRs that have shipped. I know
someone will say its not needed because its only on SOX
with issues and its only 1% but...
Average EPS for Q3 is 0.48. Judging by what I
hear about sales of the NIR and Radius, BSX will make
it. (This is the revised estimate from last week of
course). Share price regained its loss on Thursday. I
think we have seen it bottom. As I said before I expect
it to remain in the 45-55 range until positive news
in Q4 or when the results of Q4 are out.
with the Schneider deal BSX has gained significant
patent rights in the US. One of these is the rapid
exchange balloon catheter(which is a real winner, and
which has been the main seller in Europe where it
didn't need the patent rights); I would expect BSX to
launch a combination of this balloon with the NIR stent
next year which will mean even more market
This stock wiil hit 80 again so buy now and hold for 6
The Wallstent by Schnieder has just recently been
approved for coronary use, it has been used for biliary,
trachichial/bronchial, and peripheral use for many years and has been
the leading stent in interventional radiology. Just
trying to add some info from the other spectrum,
interventional radiolog. No BS here!!!